Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.13 – $7.15
70% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.9M | $5.4M | $1.9M | $9.0M | $18.2M | $13.4M | $3.4M | $2.1M |
| Cost of revenue | $1.2M | $877.6K | $720.9K | $4.1M | $13.1M | $7.8M | $2.4M | $1.3M |
| Gross profit | $2.7M | $4.5M | $1.2M | $4.9M | $5.1M | $5.5M | $1.0M | $838.9K |
| Gross margin | 69.1% | 83.7% | 62.7% | 54.6% | 27.8% | 41.4% | 29.6% | 39.3% |
| R&D | $2.8M | $3.0M | $3.3M | $3.8M | $3.9M | $3.7M | $3.6M | $6.0M |
| Operating income | −$11.6M | −$9.1M | −$12.5M | −$12.3M | −$14.0M | −$11.0M | −$14.0M | −$16.0M |
| EBITDA | −$11.1M | −$8.1M | −$12.2M | −$11.7M | −$12.7M | −$9.6M | −$13.3M | $384.2K |
| Net income | −$11.7M | −$8.6M | −$12.8M | −$16.0M | −$8.4M | −$9.9M | −$7.0M | −$69.5M |
| Net margin | -299.6% | -160.2% | -660.9% | -177.6% | -46.1% | -74.4% | -203.8% | -3251.7% |
| EPS (diluted) | -317.12 | -187.30 | -65.14 | -46.35 | -18.68 | -15.21 | -1.82 | -134.23 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7M | $-82.50 | $-82.50–$-82.50 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds APDN.
No tracked institution reports a position in APDN as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-03-14 | 1-for-50reverse |
| 2024-04-25 | 1-for-20reverse |
| 2019-11-01 | 1-for-40reverse |
| 2014-10-29 | 1-for-60reverse |
No one on the platform has traded APDN yet.
| $3M |
| — |
| DMTKQDermTech, Inc. | $0.00 | +0.00% | $3496 | — |
| MDVLMedAvail Holdings, Inc. | $1.80 | -43.22% | $3M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 6.0× sales vs its 59.3× historical median P/S.
Fair value ≈ $56.03 · price $5.62 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.